INTRODUCTION
============

Osteoarthritis can be defined as a type of articular diseases resulting from the destruction of articular cartilage and subchondral bone. It is the most common degenerative joint disease, especially in elderly people. The joint stiffness and pain have been known to be the most common symptoms of osteoarthritis and inflammation in synovial tissues, the formation of bone spurs, joint cartilage degeneration, and changes in the underlying bone are its pathological characteristics ([@b68-bt-27-503]; [@b1-bt-27-503]). Mechanical stress, injury of the articular structure, inflammation, oxidative stress, and older age were reported to be the etiological factors of osteoarthritis. However, an effective and definitive method for the cure or, at least, management of osteoarthritis has not yet been developed, since the molecular mechanism of the destruction of articular tissues has not been clearly elucidated ([@b64-bt-27-503]; [@b70-bt-27-503]; [@b102-bt-27-503]). To date, the final goal in the management of osteoarthritis is to regulate symptoms including pain, improve the quality of life, and mitigate disability ([@b9-bt-27-503]). Currently, pharmacological management and non-pharmacological management are used for the regulation of osteoarthritis ([Table 1](#t1-bt-27-503){ref-type="table"}). For the non-pharmacological management of osteoarthritis, body weight loss, exercise, and articular surgery are recommended ([@b4-bt-27-503]). The pharmacological interventions for osteoarthritis include the use of nonsteroidal anti-inflammatory drugs (NSAIDs), symptomatic slow-acting drugs for osteoarthritis, analgesics, putative disease-modifying agents, bone-acting agents, agents for intraarticular injection such as corticosteroids and hyaluronic acid ([@b23-bt-27-503]; [@b34-bt-27-503]; [@b42-bt-27-503]). However, these agents are ineffective against the root-cause of osteoarthritis, cause a multitude of severe side effects, and are inadequate for the long-term management of osteoarthritis ([@b85-bt-27-503]; [@b59-bt-27-503]). The onset and progression of osteoarthritis are attributed to various inflammatory cytokines in joint tissues and fluids that are produced by chondrocytes and/or interact with chondrocytes, as well as to low-grade inflammation in intra-articular tissues ([@b1-bt-27-503]). Disruption of the equilibrium between the synthesis and degradation of the cartilage of the joint is the major cause of osteoarthritis ([@b68-bt-27-503]). Thus, developing a promising pharmacological tool to restore the equilibrium between the synthesis and degradation of osteoarthritic joint cartilage can be a useful strategy for effective osteoarthritis management. In this review, we attempted to summarize the results of research for searching a novel candidate agent that could regulate osteoarthritis by restoring the equilibrium between cartilage synthesis and degradation. We particularly focused on studies of medicinal plants and natural products derived from them, in order to shed light on the potential pharmacotherapy of osteoarthritis.

CURRENT CONVENTIONAL PHARMACOTHERAPY FOR THE MANAGEMENT OF OSTEOARTHRITIS
=========================================================================

Thus far, NSAIDs, symptomatic slow-acting drugs for osteoarthritis, analgesics, putative disease-modifying agents, bone-acting agents, and agents for intra-articular injection including corticosteroids and hyaluronic acid have been used as pharmacological agents for the management of osteoarthritis. However, it has been reported that these agents are not efficacious against the root-cause of osteoarthritis, cause many severe side effects, and are not adequate for the long-term management of osteoarthritis ([@b85-bt-27-503]; [@b59-bt-27-503]).

NSAIDs
------

NSAIDs are the most frequently used agents for the management of osteoarthritis. They showed moderate activity against osteoarthritic pain; however, it is recommended that NSAIDs be used intermittently or for a short period. NSAIDs can be classified as cyclooxygenase-2 (COX-2)-selective agents and non-selective agents. COX-2-selective agents are celecoxib, meloxicam, rofecoxib, valdecoxib, polmacoxib, and etoricoxib. Non-selective COX inhibitors are diclofenac, diflunisal, etodolac, flurbiprofen, ibuprofen, indomethacin, ketoprofen, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, tolmetin, azapropazone, carprofen, meclofenamate, tenoxicam, etofenamate, nimesulide, and tiaprofenic acid. Among these, diclofenac, naproxen, celecoxib, rofecoxib, and etoricoxib have been frequently used to manage osteoarthritic pain ([@b33-bt-27-503]).

Symptomatic slow-acting drugs in osteoarthritis
-----------------------------------------------

Glucosamine hydrochloride, chondroitin sulfate, diacerein, and glucosamine sulfate are classified as symptomatic slow-acting drugs for osteoarthritis. Prescription-grade chondroitin sulfate and glucosamine sulfate are recommended as first-line agents for the pharmacological management of genicular osteoarthritis. These agents have been reported to show an improvement in physical function and pain in osteoarthritis ([@b12-bt-27-503]).

Analgesics
----------

Acetaminophen, tramadol, and opioids including oxycodone are used to control the pain in osteoarthritis during a short period, although these agents are not associated with an improvement in pain in the long term ([@b39-bt-27-503]; [@b69-bt-27-503]).

Putative disease-modifying agents
---------------------------------

Sprifermin, doxycycline, PG-116800 (a matrix metalloproteinase inhibitor), and cindunistat can be classified as putative disease-modifying agents for osteoarthritis. While clinical trials to prove the efficacy of these agents are ongoing, thus far, these agents have not shown significant improvements in structural changes in the joint ([@b77-bt-27-503]).

Bone-acting agents
------------------

Risedronate, zoledronic acid, strontium ranelate, calcitonin, and vitamin D are classified as bone-acting agents for the regulation of osteoarthritis. They are antiresorptive agents or bone-forming agents. Bone-acting agents showed some potential benefit in the turnover of subchondral bone, although these agents did not show a significant improvement in structural changes of the joint ([@b5-bt-27-503]).

Agents for intra-articular injection
------------------------------------

Corticosteroids including triamcinolone, betamethasone, and methylprednisolone and hyaluronic acid are classified as agents for intra-articular injection. Generally, to regulate the acute exacerbation of genicular osteoarthritis, intra-articular injection of corticosteroids is recommended. During the initial 2 to 3 weeks of intervention, intra-articular injection of corticosteroids showed a greater beneficial effect. Furthermore, during follow-up periods of 3 and 6 months, intra-articular injection of hyaluronic acid showed a greater beneficial effect. The combinatorial administration of corticosteroids and hyaluronic acid by intra-articular injection showed a moderate beneficial effect on the pathophysiology of osteoarthritis. However, for long-term pain, intra-articular injection of hyaluronic acid did not show a significant improvement ([@b6-bt-27-503]).

SEARCH FOR NOVEL CANDIDATE AGENTS FOR REGULATING OSTEOARTHRITIS FROM MEDICINAL PLANTS AND NATURAL PRODUCTS DERIVED FROM THEM
============================================================================================================================

Inflammation has been reported to be involved in the loss of articular cartilage in osteoarthritis and this mild inflammatory reaction leads to the development of the disease ([@b57-bt-27-503]). TNF-α and IL-1β, the main catabolic inflammatory cytokines, play a pivotal role in the process of articular cartilage degradation. These cytokines increase the expression and catabolic activity of matrix metalloproteinases (MMPs) on articular cartilage destruction via activation of the NF-κB signaling pathway. Further, the activated NF-κB signaling pathway and other intracellular signaling pathways in concert aggravate the cartilage degeneration ([@b25-bt-27-503]; [@b8-bt-27-503]). The extracellular matrix present in the joint cartilage regulates the physiological function and metabolism of chondrocytes. Collagen type II and proteoglycans including hyaluronic acid, glycosaminoglycan, and chondroitin sulfate consist of the extracellular matrix. Chondrocyte death (apoptosis), the induction of extracellular matrix degradation, and compromised production of the extracellular matrix might provoke articular cartilage destruction in osteoarthritis ([@b32-bt-27-503]; [@b13-bt-27-503]). Based on this information ([Table 2](#t2-bt-27-503){ref-type="table"}), in the present section of this review, we provide an overview of the results of many studies aimed at searching for novel candidate agents for regulating osteoarthritis through control of the equilibrium between the synthesis and degradation of cartilage, especially from medicinal plants and natural products derived from them ([Table 3](#t3-bt-27-503){ref-type="table"}). The medicinal plants and natural products derived from them are listed according to alphabetical order hereon.

Achyranthes bidentata
---------------------

Polysaccharides contained in *Achyranthes bidentata* induced the transition of the G1/S phases of the cell cycle and expression of collagen type II in chondrocytes. They stimulated the expression of CDK6, CDK4, and cyclin D1, promoting the cell cycle and proliferation of chondrocytes ([@b96-bt-27-503]).

Aconitum carmichaelii
---------------------

*Aconitum carmichaelii* showed preventive activity against the decrease in bone density and degeneration of cartilage. It stimulated the proliferation of chondrocytes ([@b87-bt-27-503]).

Arnica montana
--------------

In a rat model of collagen-induced arthritis (CIA), the total extract of *Arnica montana* showed an anti-inflammatory effect, in which was reflected by decreased levels of IL-6, NO, IL-1β, TNF-α, and IL-12. The extract also showed an antioxidative effect ([@b83-bt-27-503]).

Astaxanthin
-----------

Astaxanthin, a carotenoid, showed anti-inflammatory and antioxidative effects on cartilage. It suppressed the expression of MMPs including MMP-13, MMP-3, and MMP-1. Astaxanthin also inhibited the phosphorylation of p38 mitogen-activated protein kinase (MAPK) and p44/42 MAPK, and the degradation of inhibitory kappa Bα (IκBα) in interleukin-1β (IL-1β)-stimulated chondrocytes ([@b18-bt-27-503]).

Apigenin
--------

Apigenin, an anti-inflammatory flavonoid compound, was reported to suppress the gene expression of MMPs including MMP-1, MMP-13, MMP-3, a disintegrin and metalloproteinase with thrombospondin motif-5 (ADAMTS-5), and ADAMTS-4, in primary cultured rabbit chondrocytes. It also decreased the proteolytic activity and secretion of MMP-3. Furthermore, intra-articular injection of apigenin inhibited the *in vivo* production of MMP-3 protein in the rat knee joint ([@b74-bt-27-503]).

Apis mellifera
--------------

Venom from the bee species, *Apis mellifera*, was reported to suppress the expression of MMP-8 and MMP-1 stimulated by TNF-α by affecting the NF-κB signaling pathway. Furthermore, bee venom blocked the TNF-α-induced phosphorylation of ERK1/2, Akt, and JNK ([@b44-bt-27-503]).

Astragalin
----------

The antioxidative and anti-inflammatory flavonoid compound, kaempferol-3-O-glucopyranoside, also known as astragalin, was reported to inhibit the IL-1β-stimulated activation of NF-κB and MAPK in chondrocytes in patients with osteoarthritis. Astragalin also decreased the production of prostaglandin E~2~ (PGE~2~) and nitric oxide (NO) and the expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) ([@b67-bt-27-503]).

Aucubin
-------

Aucubin, a natural anti-inflammatory product derived from diverse medicinal plants including *Eucommia ulmoides*, suppressed the inflammatory response through blocking the phosphorylation and degradation of IκB and the translocation of NF-κB p65 in rat articular chondrocytes stimulated by IL-1β. Furthermore, the compound decreased the production of NO and expression of iNOS, COX-2, and MMPs ([@b94-bt-27-503]).

Baicalein
---------

Baicalein, a natural product derived from *Scutellaria baicalensis*, has been reported to inhibit the expression of MMP-13 and MMP-3 in human chondrocytes. It also stimulated the production of glycosaminoglycan (GAG) and collagen type II through by affecting the phosphorylation of ERK and p38 ([@b104-bt-27-503]).

Bauhinia championii
-------------------

Polysaccharides present in *Bauhinia championii* were reported to stimulate the proliferation of chondrocytes and promote the transition of the G1/S phases of the cell cycle. These polysaccharides activated the intracellular signaling pathways pivotal in the maintenance of articular cartilage ([@b62-bt-27-503]).

Bavachin
--------

Bavachin, a phytoestrogen present in a medicinal plant *Psoralea corylifolia*, was reported to protect against IL-1β-stimulated cartilage impairment via suppressing the degradation of IκBα and nuclear translocation of NF-κB ([@b20-bt-27-503]).

Berberine
---------

Berberine, an anti-inflammatory natural product derived from *Rhizoma coptidis*, has been reported to block the degradation of cartilage and suppress NF-κB signaling pathways in a human chondrosarcoma cell line. Furthermore, it showed a potential chondroprotective effect through inhibiting the apoptosis of chondrocytes and the gene and protein expression of MMP-13, MMP-3, and MMP-1 ([@b97-bt-27-503]; [@b105-bt-27-503]; [@b65-bt-27-503]; [@b108-bt-27-503]).

Betulin
-------

Betulin, a natural anti-inflammatory compound isolated from Betulae Cortex, inhibited IL-1β-induced gene expression of MMP-13, MMP-1, and MMP-3 although it stimulated type II collagen gene expression in primary cultured chondrocytes. Furthermore, intra-articular injection of betulin blocked *in vivo* MMP-3 production in knee joint chondrocytes ([@b78-bt-27-503]).

Biochanin A
-----------

Biochanin A contained in red clover was reported to block IL-1β-induced expression of MMPs and restore the compromised expression of TIMP-1 via affecting the NF-κB signaling pathway in chondrocytes ([@b98-bt-27-503]).

Boswellia serrata
-----------------

A preparation of *Boswellia serrata* (BS) extract has been reported to inhibit the degeneration of cartilage by MMP-13, MMP-9, and MMP-13 and inflammation in arthritis by suppressing the functions of NO, COX-2, PGE~2~, and intercellular adhesion molecule-1 (ICAM-1) ([@b10-bt-27-503]; [@b82-bt-27-503]). In an animal model of CIA, BS extract showed antioxidative and anti-inflammatory effects ([@b89-bt-27-503]). In a clinical trial, treatment with the extract decreased pain and increased functionality in patients with knee osteoarthritis ([@b91-bt-27-503]). Boswellic acids, which are natural products isolated from BS, were reported to block anti-inflammatory activity by inhibiting the NF-κB signaling pathway, in experimental models of arthritic inflammation ([@b51-bt-27-503]; [@b3-bt-27-503]).

Catechins
---------

Catechins, the main polyphenolic compounds present in tea, showed potential anti-arthritic effects, and epigallocatechin-3-gallate, a representative catechin, has been reported to exert chondroprotective activity by inhibiting IL-1β-stimulated expression of IL-8, PGE2, and COX-2, in human synovial fibroblasts ([@b40-bt-27-503]). In an animal model, epigallocatechin-3-gallate decreased the levels of MMP-8, MMP-13, ADAMTS-5, MMP-1, and MMP-3 in articular cartilage ([@b60-bt-27-503]).

Celastrol
---------

In primary human osteoarthritic chondrocytes, celastrol, a natural product inhibiting heat shock protein (HSP) 90β, showed a suppressive effect on IL-1β-stimulated expression of MMP-13, MMP-3, MMP-1, COX-2, and iNOS-2 ([@b26-bt-27-503]).

Clematis chinensis
------------------

In an animal model of osteoarthritis established by the intra-articular injection of monosodium iodoacetate, a saponin fraction isolated from *Clematis chinensis*, showed an inhibitory effect against cartilage damage and destruction of the joint by suppressing the decomposition of the extracellular matrix and chondrocyte injury ([@b99-bt-27-503]).

Crocin
------

Crocin, a natural compound derived from *Crocus sativus*, was reported to block both the expression of MMP-13, MMP-3, and MMP-11 by inhibiting the NF-κB signaling pathway in articular chondrocytes and the degeneration of cartilage *in vivo* ([@b27-bt-27-503]).

Curcumin
--------

Curcumin, a natural compound isolated from *Curcuma longa* (CL), is a known anti-inflammatory agent and regulates diverse inflammatory statuses including osteoarthritis. The compound showed ameliorative effects on inflammation of the joint in an animal model of arthritis ([@b72-bt-27-503]). A preparation of CL total extract exerted an inhibitory effect against periarticular tissue damage and joint inflammation in an *in vivo* arthritis model via inhibiting the NF-κB signaling pathway ([@b29-bt-27-503]).

Delphinidin
-----------

In osteoarthritic chondrocytes, delphinidin, an antioxidative anthocyanidin found in various vegetables and fruits, blocked the expression of COX-2 and PGE2. Delphinidin also suppressed IL-1β-induced NF-κB signaling by affecting IRAK-1 phosphorylation ([@b38-bt-27-503]).

Eucommia ulmoides
-----------------

An aqueous extract of *Eucommia ulmoides* showed antiosteoarthritic effects, based on histopathological examination of articular tissues and inhibitory regulation of serum and synovial fluid levels of MMP-13, MMP-3, and MMP-1 ([@b66-bt-27-503]; [@b100-bt-27-503]).

Ferulic acid
------------

A natural product present in *Angelica sinensis*, ferulic acid, showed the potency of an anti-osteoarthritic agent by blocking the hydrogen peroxide (H~2~O~2~)-induced expression of MMP-13 and MMP-1 in chondrocytes ([@b16-bt-27-503]).

GCSB-5
------

GCSB-5 is a standardized extract from a mixture of six herbs including *Saposhnikovia divaricata*, *Achyranthes japonica*, *Acanthopanax sessiliflorus*, *Cibotium barometz*, *Glycine max*, and *Eucommia ulmoides*, developed in South Korea for the regulation of osteoarthritis in knee joint ([@b22-bt-27-503]). In an animal model of osteoarthritis established using monosodium iodoacetate, intra-articular injection of GCSB-5 blocked the production of anti-type II collagen antibody and PGE2, regulating the balance of cytokines and inflammatory mediators ([@b56-bt-27-503]). In a clinical trial, the safety and efficacy of GCSB-5 were comparable to those of celecoxib, a selective COX-2 inhibitor, in the treatment of knee joint osteoarthritis ([@b76-bt-27-503]).

Gentiopicroside
---------------

Gentiopicroside derived from *Gentiana macrophylla* suppressed the IL-1β-stimulated expression of MMPs and the phosphorylation of JNK, ERK, and p38, in murine articular chondrocytes. Furthermore, it promoted type II collagen production ([@b106-bt-27-503]).

Ginsenosides
------------

Ginsenosides isolated from *Panax ginseng* showed various biological effects. Ginsenoside Rb1, a subtype of ginsenosides, suppressed the levels of MMP-13 and MMP-1, NO, iNOS, IL-1β, and TNF-α, and promoted the expression of type II collagen ([@b55-bt-27-503]; [@b21-bt-27-503]). Ginsenosides Rg1, Rg3, Rg5, Rk1, Rf, Rd, Rc, and F4 were reported to exert chondroprotective effect ([@b41-bt-27-503]; [@b58-bt-27-503]).

Harpagophytum procumbens
------------------------

*Harpagophytum procumbens* has been utilized as a folk medicine for managing musculoskeletal degenerative diseases including osteoarthritis. The total extract of *Harpagophytum procumbens* exerted chondroprotective effects via blocking the activity of MMPs and elastase and the production of inflammation mediators including IL-1β and TNF-α ([@b28-bt-27-503]). In a clinical trial, diverse HP extracts showed ameliorative effects on limited movement and pain in patients with osteoarthritis of the hip and knee ([@b15-bt-27-503]; [@b24-bt-27-503]; [@b95-bt-27-503]).

Honokiol
--------

Honokiol, a major natural compound isolated from *Magnolia officinalis*, blocked IL-1β-stimulated expression of MMP-13, IL-6, iNOS, NO, COX-2, and PGE2 via the NF-κB signaling pathway ([@b19-bt-27-503]).

Icariin
-------

Icariin, a compound derived from *Epimedium pubescens*, was reported to inhibit the IL-1β-stimulated expression of MMP-13 in chondrocytes. Furthermore, it enhanced extracellular matrix synthesis and showed chondroprotective effects ([@b61-bt-27-503]).

Luteolin
--------

Luteolin, a flavonoid compound derived from Lonicerae flos, blocked IL-1β-stimulated gene expression, secretion, and enzyme activity of MMP-3 in cultured articular chondrocytes. It inhibited the gene expression levels of ADAMTS-4, MMP-13, MMP-1, and ADAMTS-5, and affected the *in vivo* production of MMP-3 protein in the rat knee joint ([@b48-bt-27-503]).

Monotropein
-----------

Monotropein, a compound present in *Morinda officinalis*, was reported to block IL-1β-stimulated expression of MMP-13 and MMP-3 in chondrocytes ([@b92-bt-27-503]).

Morin
-----

Morin, a flavonoid compound, has been reported to exert anti-inflammatory, antioxidative, and anticancer effects. Morin blocked IL-1β-stimulated expression of MMP-13 and MMP-3 and promoted the expression of TIMP-1 via suppression of the phosphorylation of ERK1/2 and p38 ([@b17-bt-27-503]).

Oleanolic acid
--------------

Oleanolic acid, a triterpenoid compound present in various fruit and vegetables, promoted type II collagen gene expression and blocked the gene expression of ADAMTS-5, MMP-1, MMP-13, ADAMTS-4, and MMP-3. Furthermore, it decreased *in vitro* enzyme activity and *in vivo* production of MMP-3 ([@b49-bt-27-503]).

Panax notoginseng
-----------------

A preparation of *Panax notoginseng* (PN) extract suppressed the production of IL-1, iNOS, TNF-α, and MMP-13 *in vitro* ([@b14-bt-27-503]).

PG201
-----

PG201, a multi-component standardized extract of medicinal plants for managing the symptoms of osteoarthritis, showed a protective effect on the cartilage in an animal model of collagenase-induced arthritis ([@b86-bt-27-503]; [@b75-bt-27-503]). It also showed a significant effect on osteoarthritis in a clinical trial ([@b37-bt-27-503]).

Phellodendron amurense
----------------------

*Phellodendron* *amurense*, a medicinal plant with immunostimulatory and anti-inflammatory properties, was reported to protect articular cartilage via blocking IL-1β-stimulated type II collagen degradation and proteoglycan release ([@b52-bt-27-503]).

Pinocembrin
-----------

Pinocembrin contained in propolis showed a suppressive effect on MMP-13 and MMP-3 expression through affecting the NF-κB signaling pathway in human chondrocytes ([@b103-bt-27-503]).

Piperine
--------

Piperine, a natural compound present in black pepper (*Piper nigrum*), has been reported to exert a suppressive effect on IL-1β-induced elevated levels of MMPs, COX-2, NO, PGE2, and iNOS through NF-κB signaling ([@b101-bt-27-503]).

Prunetin
--------

Prunetin, a natural product found in *Glycyrrhiza glabra*, inhibited the *in vivo* production of MMP-3 stimulated by IL-1β. It also blocked the gene expression, secretion, and enzyme activity of MMP-3 in primary cultured rabbit chondrocytes ([@b71-bt-27-503]).

Resveratrol
-----------

Resveratrol, a well-known natural product derived from diverse plants including grapes, has been reported to suppress the expression of iNOS, COX-2, TNF-α, and IL-1β by blocking the NF-κB signaling pathway ([@b93-bt-27-503]). It was reported that resveratrol blocked the gene expression and secretion of MMP-3 in rabbit chondrocytes. Furthermore, it suppressed IL-1β-stimulated gene expression of various MMPs via blocking of the phosphorylation of inhibitory kappa B kinase (IKK), phosphorylation and degradation of inhibitory kappa Bα (IκBα), and phosphorylation and nuclear translocation of NF-κB p65 in human chondrocytes ([@b50-bt-27-503]).

Schisandrae Fructus
-------------------

The ethanol extract of Schisandrae Fructus showed chondroprotective activity and inhibited the expression of COX-2, MMPs, and iNOS via suppressing the phosphorylation of JNK, p38, and ERK1/2, and NF-κB signaling, in human chondrocytes ([@b43-bt-27-503]).

Sinomenine
----------

Sinomenine, a natural product derived from *Sinomenium acutum*, has been reported to decrease MMP-13 expression and glycosaminoglycan (GAG) release. It also increased TIMP-1 activity, thereby suppressing apoptosis of cells and fragmentation of DNA in chondrocytes ([@b45-bt-27-503]).

SKI306X
-------

[@b53-bt-27-503] reported that SKI306X blocked the degradation of the matrix by suppressing the gene expression, secretion and enzyme activity of MMPs, in rabbit articular cartilage. In a double-blind, controlled clinical trial, SKI 306X, a standardized extract of a mixture of three medicinal plants including *Trichosanthes kirilowii*, *Prunella vulgaris*, and *Clematis mandshurica*, showed a pain-relieving effect without significant adverse effects, in knee osteoarthritis patients ([@b47-bt-27-503]). In another clinical trial, SKI306X showed a protective effect on the cartilage in patients with knee osteoarthritis ([@b54-bt-27-503]).

Symphytum officinalis
---------------------

Topical administration of a preparation of *Symphytum officinalis* extract could regulate pain and articular mobility in knee osteoarthritis ([@b35-bt-27-503]).

Tetramethylpyrazine
-------------------

Tetramethylpyrazine present in *Ligusticum wallichii* has been reported to suppress the apoptosis of chondrocytes and the expression of iNOS, MMP-13, COX-2, and MMP-3 and promote the expression of collagen type II and TIMP-1 ([@b46-bt-27-503]; [@b63-bt-27-503]).

Tetrandrine
-----------

Tetrandrine isolated from *Stephania tetrandra* has been reported to exert the chondroprotective activity via blocking IL-1β-stimulated expression of MMPs and β-catenin signaling and promoting the expression of TIMP-1, *in vitro* and *in vivo* ([@b107-bt-27-503]). It also blocks the expression of PGE~2~, IL-6, TNF-α, IL-1β, and NO via blocking NF-κB signaling in articular inflammation ([@b31-bt-27-503]).

Withania somnifera
------------------

A preparation of the total extract of *Withania somnifera*, a medicinal plant used as a folk remedy for alleviating osteoarthritis, exerted a potential protective effect on the degradation of articular tissues by inhibiting collagenase activity ([@b30-bt-27-503]). In a clinical trial, *Withania somnifera* extract showed a significant pain-relieving effect on osteoarthritic knee joint ([@b79-bt-27-503]). Withaferin A, the major active natural compound in *Withania somnifera*, showed anti-inflammatory action by controlling TNF-α, the paw volume, lipid peroxidation, and lysosomal enzymes, in an animal model of arthritis ([@b80-bt-27-503]).

Willow bark
-----------

Willow bark has long been utilized as a folk remedy for managing pain. A preparation of willow bark extract showed an inhibitory effect on the development of oxidative stress and production of proinflammatory cytokines in an animal model of arthritis ([@b84-bt-27-503]). This effect may be dependent on the blocking of monocyte activation by suppressing the activity of COX-2 and TNF-α ([@b11-bt-27-503]). In a few clinical trials, willow bark extract decreased the pain in osteoarthritis patients ([@b81-bt-27-503]; [@b7-bt-27-503]; [@b88-bt-27-503]).

Wogonin
-------

Wogonin, a flavonoid compound showing anti-inflammatory activity, exerted chondroprotective effects *in vitro* and *in vivo*. In cultured articular chondrocytes, wogonin promoted the expression of collagen type II and suppressed MMP expression. Furthermore, intra-articular injection of wogonin blocked the gene expression, production, and activity of MMP-3, and *in vivo* production of MMP-3 ([@b73-bt-27-503]).

Zingiber officinale
-------------------

Ginger, *Zingiber officinale*, has been reported to show anti-inflammatory effects by elevating the serum level of corticosterone and blocking COX and lipoxygenase (LOX) ([@b36-bt-27-503]; [@b90-bt-27-503]). A preparation of *Zingiber officinale* extract controlled pain in patients with osteoarthritis ([@b2-bt-27-503]).

CONCLUSION AND FUTURE DIRECTION FOR OSTEOARTHRITIS RESEARCH
===========================================================

As mentioned previously, the use of agents for the conventional pharmacological management of osteoarthritis alone cannot address the root-cause of osteoarthritis. Furthermore, these agents show diverse and severe side effects and are not adequate for long-term management of osteoarthritis. On the other hand, a majority of natural products have shown inhibitory effects on proinflammatory cytokine-induced expression and catabolic activity of MMPs in articular cartilage via activation of the NF-κB signaling pathway. They showed suppressive effects on the apoptosis of chondrocytes, induction of extracellular matrix degradation, and decrease in the production of the extracellular matrix, in articular cartilage. However, there is no front-line candidate natural product and/or medicinal plant to reverse or prevent the development of the signs and symptoms of osteoarthritis, despite the many experimental and clinical studies conducted thus far ([Fig. 1](#f1-bt-27-503){ref-type="fig"}). Therefore, it is timely to develop an optimal candidate through optimization of the chemical structures of natural products showing the strongest anti-inflammatory, anti-apoptotic, and anti-catabolic activities, to restore the equilibrium between the synthesis and degradation of articular cartilage. Additionally, after joint injury, fibrotic cartilage is generated instead of the normal hyaline cartilage. Thus, it is ideal to develop a novel anti-fibrotic and anti-inflammatory candidate molecule that would facilitate the synthesis of the normal hyaline cartilage in the process of regeneration of articular cartilage.
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###### 

The management of osteoarthritis

  -------------------------------- -----------------------------------------------------------------------------------
  Pharmacological management       Nonsteroidal anti-inflammatory drugs (NSAIDs)\
                                   Symptomatic slow-acting drugs in osteoarthritis Analgesics\
                                   Putative disease-modifying agents\
                                   Bone-acting agents\
                                   Agents for intraarticular injection including corticosteroids and hyaluronic acid

  Non-pharmacological management   Body weight loss\
                                   Taking exercises\
                                   Articular surgery
  -------------------------------- -----------------------------------------------------------------------------------

###### 

The major drug targets of some natural products

  ----------------------------------------------------------------------------
  Induction of extracellular matrix degradation by matrix metalloproteinases
  Compromised production of the extracellular matrix
  The apoptosis and proliferation of chondrocytes
  Inflammation and oxidative stress generated in articular tissues
  ----------------------------------------------------------------------------

###### 

The list of medicinal plants and natural products showing the effect on the pathophysiology of osteoarthritis

  ------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------
  Medicinal plants                      *Achyranthes bidentata* ([@b96-bt-27-503])\
                                        *Aconitum carmichaeli* ([@b87-bt-27-503])\
                                        *Arnica Montana* ([@b83-bt-27-503])\
                                        *Apis mellifera* ([@b44-bt-27-503])\
                                        *Bauhinia championi* ([@b62-bt-27-503])\
                                        *Boswellia serrata* ([@b51-bt-27-503]; [@b10-bt-27-503]; [@b3-bt-27-503]; [@b82-bt-27-503]; [@b91-bt-27-503]; [@b89-bt-27-503])\
                                        *Clematis chinensis* ([@b99-bt-27-503])\
                                        *Eucommia ulmoides* ([@b66-bt-27-503]; [@b100-bt-27-503])\
                                        GCSB-5 ([@b76-bt-27-503]; [@b22-bt-27-503]; [@b56-bt-27-503])\
                                        *Harpagophytum procumbens* ([@b15-bt-27-503]; [@b24-bt-27-503]; [@b95-bt-27-503])\
                                        *Panax notoginseng* ([@b14-bt-27-503])\
                                        PG201 ([@b86-bt-27-503]; [@b75-bt-27-503]; [@b37-bt-27-503])\
                                        *Phellodendron amurense* ([@b52-bt-27-503])\
                                        Schisandrae Fructus ([@b43-bt-27-503])\
                                        SKI306X ([@b47-bt-27-503]; [@b53-bt-27-503]; [@b54-bt-27-503])\
                                        *Symphytum officinalis* ([@b35-bt-27-503])\
                                        *Whitania somnifera* ([@b80-bt-27-503]; [@b30-bt-27-503]; [@b79-bt-27-503])\
                                        Willow bark ([@b81-bt-27-503]; [@b7-bt-27-503]; [@b88-bt-27-503])\
                                        *Zingiber officinalis* ([@b2-bt-27-503]; [@b36-bt-27-503]; [@b90-bt-27-503])

  Natural products (single compounds)   Astaxanthin ([@b18-bt-27-503])\
                                        Apigenin ([@b74-bt-27-503])\
                                        Astragalin ([@b67-bt-27-503])\
                                        Aucubin ([@b94-bt-27-503])\
                                        Baicalein ([@b104-bt-27-503])\
                                        Bavachin ([@b20-bt-27-503])\
                                        Berberine ([@b97-bt-27-503]; [@b105-bt-27-503]; [@b65-bt-27-503]; [@b108-bt-27-503])\
                                        Betulin ([@b78-bt-27-503])\
                                        Biochanin A ([@b98-bt-27-503])\
                                        Catechins ([@b60-bt-27-503])\
                                        Celastrol ([@b26-bt-27-503])\
                                        Crocin ([@b27-bt-27-503])\
                                        Curcumin ([@b29-bt-27-503]; [@b72-bt-27-503]).\
                                        Delphinidin ([@b38-bt-27-503])\
                                        Ferulic acid ([@b16-bt-27-503])\
                                        Gentiopicroside ([@b106-bt-27-503])\
                                        Ginsenosides ([@b55-bt-27-503]; [@b21-bt-27-503]; [@b41-bt-27-503]; [@b58-bt-27-503])\
                                        Honokiol ([@b19-bt-27-503])\
                                        Icariin ([@b61-bt-27-503])\
                                        Luteolin ([@b48-bt-27-503])\
                                        Monotropein ([@b92-bt-27-503])\
                                        Morin ([@b17-bt-27-503])\
                                        Oleanolic acid ([@b49-bt-27-503])\
                                        Pinocembrin ([@b103-bt-27-503])\
                                        Piperine ([@b101-bt-27-503])\
                                        Prunetin ([@b71-bt-27-503])\
                                        Resveratrol ([@b50-bt-27-503])\
                                        Sinomenine ([@b45-bt-27-503])\
                                        Tetramethylpyrazine ([@b46-bt-27-503]; [@b63-bt-27-503])\
                                        Tetrandrine ([@b107-bt-27-503]; [@b31-bt-27-503])\
                                        Wogonin ([@b73-bt-27-503])
  ------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------

[^1]: The first two authors contributed equally to this work.
